Condition
Malignant Pleural Mesothelioma, Advanced
Total Trials
4
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Recruiting2
Completed1
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06756035Phase 1Recruiting
CT-95 in Advanced Cancers Associated With Mesothelin Expression
NCT06031636RecruitingPrimary
Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma
NCT03213301Phase 2CompletedPrimary
Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.
NCT03786419Phase 2WithdrawnPrimary
A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma
Showing all 4 trials